View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
April 29, 2020

Covid-19 Healthcare Daily Update: New Parkinson’s drug launch delayed – Covid pandemic could increase levels of PTSD

By Paul Dennis

Neurocrine’s new Parkinson’s drug suffers launch delay due to Covid-19 On 27 April, Neurocrine Biosciences announced that it has received FDA approval for Ongentys (opicapone), an oral drug that is used as an add-on treatment to the standard-of-care drug, levodopa, in patients with Parkinson’s disease who experience end-of-dose motor fluctuations.

However, the company will not launch Ongentys until later in 2020, given the disruption caused by Covid-19.


Covid-19 pandemic could cause an increase in prevalence of PTSD The Covid-19 pandemic has the potential to increase stress and anxiety, both because of the fear of infection and because of uncertainty about how the outbreak will affect people socially and economically.

After the severe acute respiratory syndrome (SARS) outbreak in 2003, front-line healthcare workers and people who were self-quarantined exhibited the symptoms of PTSD.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network